Abstract
A 45-year-old woman presented with right hip pain for a month. Imaging results revealed that the left peritoneal mass was accompanied by metastases of the right sciatic branch, lung, and retroperitoneal lymph nodes. A biopsy of the left peritoneal mass was performed. The pathological morphology demonstrated clear cell adenocarcinoma. Immunohistochemical staining revealed a positive expression of keratin7 and PAX8 and a negative expression of keratin20, GCDFP-15, ER, PR, WT1, CDX2, villin, TTF-1, napsin-A, vimentin, calretinin, and GATA3. Finally, the diagnosis of primary retroperitoneal müllerian adenocarcinoma (PRMA) was confirmed. PRMA is a very rare type of primary retroperitoneal tumor. PRMA should be considered for the retroperitoneal mass.
Introduction
The retroperitoneum is a complex anatomical space containing various vital structures, making the differential diagnosis of masses in this region particularly challenging. While Müllerian adenocarcinomas typically arise from the female reproductive tract (uterus, ovaries, or fallopian tubes), they can rarely manifest as primary tumors within the retroperitoneum. These are known as Primary Retroperitoneal Müllerian Adenocarcinomas (PRMA).
PRMA is an aggressive malignancy that is often misdiagnosed due to its rarity and its tendency to mimic metastatic disease from other primary sites, such as the lungs, digestive tract, or kidneys. This report details a case of PRMA in a 45-year-old woman, emphasizing the critical role of immunohistochemical (IHC) profiling in achieving an accurate diagnosis.
Case Presentation
A 45-year-old female patient presented with a one-month history of persistent right hip pain. Initial clinical evaluations and a review of her medical history were conducted to map the progression of her symptoms and subsequent diagnostic interventions.
Computed Tomography (CT) imaging identified a 58 × 43-mm cystic-solid mass in the left retroperitoneum. Further staging revealed extensive metastases involving the lungs, retroperitoneal lymph nodes, and bone (specifically the right ischia). Notably, gynecological examinations, including ultrasound, showed a normal uterus and ovaries, ruling out a primary pelvic malignancy.
Diagnostic Investigation and Pathology
To determine the nature of the mass, a needle biopsy was performed. Histopathological examination using Hematoxylin and Eosin (H&E) staining revealed a clear cell adenocarcinoma morphology. However, given the location, a broad panel of immunohistochemical markers was required to exclude more common primary sites.
The tumor exhibited a specific "fingerprint": it was positive for Keratin 7 (K7) and PAX8, while testing negative for markers associated with the digestive tract (CK20, CDX2, villin), lungs (TTF-1, napsin-A), and breasts (GCDFP-15, GATA3). The PAX8/K7 signature is highly characteristic of Müllerian-derived tissues. Since the primary reproductive organs were healthy, the diagnosis of PRMA was confirmed.
Discussion
The origin of Müllerian tumors in the retroperitoneum remains a subject of debate. Two primary theories exist:
- Coelomic Metaplasia: The theory that the mesothelial lining of the abdominal cavity undergoes a transformation into Müllerian-type epithelial tissue.
- Ectopic Tissue: The development of cancer from "supernumerary" ovarian tissue or ectopic endometriosis that migrated to the retroperitoneum during embryonic development.
PRMA is notoriously aggressive. In this case, the patient already presented with distant metastases at the time of her first symptom. Treatment involved a multimodal approach: platinum-based chemotherapy (carboplatin and paclitaxel) and 45-Gy intensity-modulated radiotherapy. When the disease progressed to the liver, the patient was transitioned to targeted therapy with sevotinib (a MET inhibitor), which provided a period of disease stabilization.
Conclusion
Primary retroperitoneal müllerian adenocarcinoma is a rare but important differential diagnosis for retroperitoneal masses, especially when imaging fails to identify a primary tumor in the pelvic organs. The combination of clear cell morphology and a PAX8+/K7+ IHC profile is essential for diagnosis. Given the lack of standardized treatment guidelines, further research into molecular drivers and targeted therapies is necessary to improve outcomes for patients with this aggressive malignancy.
Summary updated